Martino Picardo, CEO Stevenage Bioscience Catalyst
Martino is the first CEO of the Stevenage Bioscience Catalyst an ambitious concept to develop an Incubator and Accelerator, followed by a world class Science Park for the Life Sciences sector. Martino has a PhD in Biochemistry from Cardiff University and spent 4 years at Baylor College Of Medicine, Houston, TX in Cardiovascular research. Martino joined Amersham International in 1991 and subsequently went on to manage the R&D Technology Transfer Group, based in Cardiff and developing high throughput screening technologies for the Pharmaceutical sector. Following the merger of Amersham with Pharmacia Biotech, Martino became the Science Director for the Cardiff site , Martino then became a Business Manager for Manchester Biotech Ltd. and subsequently Manchester Innovation Ltd. in June 1999. When the Universities of Manchester and UMIST merged, he became Managing Director of UMIC and MICL and is also currently a Board member of UKBI. Martino is also acting Chairman for a start-up company, sri Forensics Ltd and has previously been on the Board of Cartesian Technologies , BIONOW Steering Committee and was also a non -executive Director for Queen Mary Bioenterprise Ltd (2009-Aug 2010).. Martino is now also a Board member of the Hertfordshire LEP.
Stevenage Bioscience Catalyst campus is a unique bioscience community created to provide small biotech and life sciences companies and start-ups with access to the expertise, networks and scientific facilities traditionally associated with multinational pharmaceutical companies.
A key aim of Stevenage Bioscience Catalyst is to pioneer a culture of open-innovation that will place the UK bioscience sector at the forefront of worldwide biomedical discovery and deliver cutting edge healthcare solutions. Supported by Government, business, and the charitable sector, Stevenage Bioscience Catalyst campus offers a fertile environment for scientific innovation and commercial success.